Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Total Debt (2016 - 2025)

Historic Total Debt for Trinity Biotech (TRIB) over the last 14 years, with Q2 2025 value amounting to $84.8 million.

  • Trinity Biotech's Total Debt rose 2602.71% to $84.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $84.8 million, marking a year-over-year increase of 2602.71%. This contributed to the annual value of $74.0 million for FY2024, which is 8222.96% up from last year.
  • As of Q2 2025, Trinity Biotech's Total Debt stood at $84.8 million, which was up 2602.71% from $74.0 million recorded in Q4 2024.
  • Over the past 5 years, Trinity Biotech's Total Debt peaked at $84.8 million during Q2 2025, and registered a low of $39.8 million during Q2 2023.
  • Over the past 4 years, Trinity Biotech's median Total Debt value was $49.2 million (recorded in 2023), while the average stood at $56.3 million.
  • Its Total Debt has fluctuated over the past 5 years, first crashed by 3547.33% in 2023, then surged by 8222.96% in 2024.
  • Quarter analysis of 4 years shows Trinity Biotech's Total Debt stood at $44.3 million in 2022, then decreased by 8.28% to $40.6 million in 2023, then skyrocketed by 82.23% to $74.0 million in 2024, then rose by 14.46% to $84.8 million in 2025.
  • Its Total Debt stands at $84.8 million for Q2 2025, versus $74.0 million for Q4 2024 and $66.4 million for Q3 2024.